Back to search

Peptide record

TPDB08068

Camel Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08068
Camel
Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb dbAMP 3.0 CellPPD-MOD CPPsite3.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 15-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KWKLFKKIGAVLKVL
Physicochemical Analysis
C89H151N21O16
RNDCEQHMPSTY
K
1771.31
11.12
5
0
9
+5
-0.04
0.540
149.33
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
310.50
0
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
1
I
3
L
5
K
0
M
1
F
0
P
0
S
0
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 3 K: 5 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 2
Chemical Descriptors
15
C89H151N21O16
1771.31
11.12
+5
-0.04
0.540
Free
L
Linear
Free
Antimicrobial
Ceropin-Melittin hybrid
Evidence Records 43 records
Evidence 1 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

Enterococcus faecalis PCM 2673

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
aureus Cowan 1 (LC 2 uM), and S. pyogenes (LC 0.5 uM). New MIC data: active against Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gr
Evidence 2 Activity

Activity

MIC
Antibacterial
4 µg/mL

Target

Staphylococcus aureus ATCC 25923 or 9144

Source & Reference

dbAMP DRAMP

Other

genes (LC 0.5 uM). New MIC data: active against Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/
Evidence 3 Activity

Activity

MIC
Antibacterial
0.5 µg/mL

Target

S. pneumoniae ATCC 49619

Source & Reference

dbAMP DRAMP

Other

nst Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125
Evidence 4 Activity

Activity

MIC
Antibacterial
1-2 µg/mL

Target

Escherichia coli ATCC 25922 or 23506

Source & Reference

dbAMP DRAMP

Other

aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fung
Evidence 5 Activity

Activity

MIC
Antibacterial
0.125 µg/mL

Target

Klebsiella pneumoniae ATCC 700603

Source & Reference

dbAMP DRAMP

Other

pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albi
Evidence 6 Activity

Activity

MIC
Antibacterial
2 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP DRAMP

Other

E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C.
Evidence 7 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

A. niger ATCC 16404

Source & Reference

dbAMP DRAMP

Other

K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neuba
Evidence 8 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP DRAMP

Other

ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neubauer et al., 2017 ). D-form tends to mor
Evidence 9 Activity

Activity

MIC
Antibacterial
64 µg/mL

Target

C. glabrata ATCC 15126

Source & Reference

dbAMP DRAMP

Other

ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neubauer et al., 2017 ). D-form tends to more active and more stable than the L-form (D
Evidence 10 Activity

Activity

IC50
Antibacterial
7.5 µM

Target

P. falciparum

Source & Reference

dbAMP DRAMP

Other

ical anaerobic strains F. nucleatum (MIC90 8 ug/ml MIC50 4 ug/ml). Antimalarial activity:P. falciparum (IC50 7.5 uM).
Evidence 11 Activity

Activity

LC50
LC50 = 1.75 µM
Anticancer
1.75 µM

Target

Skin Cancer
B16-F10
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 12 Activity

Activity

LC50
LC50 = 1.3 µM
Anticancer
1.3 µM

Target

Renal Cancer
RENCA
Renal

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 13 Activity

Activity

LC50
LC50 = 6.2 µM
Anticancer
6.2 µM

Target

Breast Cancer
4T1
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 14 Activity

Activity

LC50
LC50 = 4.1 µM
Anticancer
4.1 µM

Target

Skin Cancer
WM1158
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 15 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

Enterococcus faecalis PCM 2673

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
aureus Cowan 1 (LC 2 uM), and S. pyogenes (LC 0.5 uM). New MIC data: active against Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gr
Evidence 16 Activity

Activity

MIC
Antifungal
4 µg/mL

Target

Staphylococcus aureus ATCC 25923 or 9144

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

genes (LC 0.5 uM). New MIC data: active against Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/
Evidence 17 Activity

Activity

MIC
Antifungal
0.5 µg/mL

Target

S. pneumoniae ATCC 49619

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

nst Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125
Evidence 18 Activity

Activity

MIC
Antifungal
1-2 µg/mL

Target

Escherichia coli ATCC 25922 or 23506

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fung
Evidence 19 Activity

Activity

MIC
Antifungal
0.125 µg/mL

Target

Klebsiella pneumoniae ATCC 700603

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albi
Evidence 20 Activity

Activity

MIC
Antifungal
2 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C.
Evidence 21 Activity

Activity

MIC
Antifungal
16 µg/mL

Target

A. niger ATCC 16404

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neuba
Evidence 22 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neubauer et al., 2017 ). D-form tends to mor
Evidence 23 Activity

Activity

MIC
Antifungal
64 µg/mL

Target

C. glabrata ATCC 15126

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neubauer et al., 2017 ). D-form tends to more active and more stable than the L-form (D
Evidence 24 Activity

Activity

IC50
Antifungal
7.5 µM

Target

P. falciparum

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ical anaerobic strains F. nucleatum (MIC90 8 ug/ml MIC50 4 ug/ml). Antimalarial activity:P. falciparum (IC50 7.5 uM).
Evidence 25 Activity

Activity

MIC
Antiparasitic
8 µg/mL

Target

Enterococcus faecalis PCM 2673

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
aureus Cowan 1 (LC 2 uM), and S. pyogenes (LC 0.5 uM). New MIC data: active against Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gr
Evidence 26 Activity

Activity

MIC
Antiparasitic
4 µg/mL

Target

Staphylococcus aureus ATCC 25923 or 9144

Source & Reference

dbAMP 3.0 DRAMP

Other

genes (LC 0.5 uM). New MIC data: active against Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/
Evidence 27 Activity

Activity

MIC
Antiparasitic
0.5 µg/mL

Target

S. pneumoniae ATCC 49619

Source & Reference

dbAMP 3.0 DRAMP

Other

nst Gram+ E. faecalis PCM 2673 (MIC 8 ug/ml), S. aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125
Evidence 28 Activity

Activity

MIC
Antiparasitic
1-2 µg/mL

Target

Escherichia coli ATCC 25922 or 23506

Source & Reference

dbAMP 3.0 DRAMP

Other

aureus ATCC 25923 or 9144 (MIC 4 ug/ml), S. pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fung
Evidence 29 Activity

Activity

MIC
Antiparasitic
0.125 µg/mL

Target

Klebsiella pneumoniae ATCC 700603

Source & Reference

dbAMP 3.0 DRAMP

Other

pneumoniae ATCC 49619 (MIC 0.5 ug/ml), Gram- E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albi
Evidence 30 Activity

Activity

MIC
Antiparasitic
2 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP 3.0 DRAMP

Other

E. coli ATCC 25922 or 23506 (MIC 1-2 ug/ml), K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C.
Evidence 31 Activity

Activity

MIC
Antiparasitic
16 µg/mL

Target

A. niger ATCC 16404

Source & Reference

dbAMP 3.0 DRAMP

Other

K. pneumoniae ATCC 700603 (MIC 0.125 ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neuba
Evidence 32 Activity

Activity

MIC
Antiparasitic
32 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP 3.0 DRAMP

Other

ug/ml), P. aeruginosa ATCC 9027 (MIC 2 ug/ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neubauer et al., 2017 ). D-form tends to mor
Evidence 33 Activity

Activity

MIC
Antiparasitic
64 µg/mL

Target

C. glabrata ATCC 15126

Source & Reference

dbAMP 3.0 DRAMP

Other

ml), fungi A. niger ATCC 16404 (MIC 16 ug/ml), C. albicans ATCC 10231 (MIC 32 ug/ml), and C. glabrata ATCC 15126 (MIC 64 ug/ml) ( Neubauer et al., 2017 ). D-form tends to more active and more stable than the L-form (D
Evidence 34 Activity

Activity

IC50
Antiparasitic
7.5 µM

Target

P. falciparum

Source & Reference

dbAMP 3.0 DRAMP

Other

ical anaerobic strains F. nucleatum (MIC90 8 ug/ml MIC50 4 ug/ml). Antimalarial activity:P. falciparum (IC50 7.5 uM).
Evidence 35 Activity

Activity

45% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
45% Hemolysis | 64 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lysine-enriched cecropin-mellitin antimicrobial peptides with enhanced selectivity. | Antimicrob Agents Chemother | 2008
Evidence 36 Activity

Activity

30% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
30% Hemolysis | 100 | µM | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Alpha,beta-dehydrophenylalanine containing cecropin-melittin hybrid peptides: conformation and activity. | J Pept Sci | 2007
Evidence 37 Activity

Activity

50% Hemolysis
Toxicity
40.2±2.2 µM
Hemolytic Cytotoxic
50% Hemolysis | 40.2±2.2 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Lysine N(epsilon)-trimethylation, a tool for improving the selectivity of antimicrobial peptides. | J Med Chem | 2010
Evidence 38 Activity

Activity

50% Hemolysis
Toxicity
18.9±1.71 µM
Hemolytic Cytotoxic
50% Hemolysis | 18.9±1.71 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Comparative analysis of internalisation, haemolytic, cytotoxic and antibacterial effect of membrane-active cationic peptides: aspects of experimental setup. | Amino Acids | 2017
Evidence 39 Activity

Activity

IC50
Toxicity
12.9±2.51 µM
Cytotoxic
IC50 | 12.9±2.51 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Comparative analysis of internalisation, haemolytic, cytotoxic and antibacterial effect of membrane-active cationic peptides: aspects of experimental setup. | Amino Acids | 2017
Evidence 40 Activity

Activity

IC50
Toxicity
3.32 µg/mL
Cytotoxic
IC50 | 3.32 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Antimicrobial Activity of Selected Antimicrobial Peptides Against Planktonic Culture and Biofilm of Acinetobacter baumannii. | Probiotics Antimicrob Proteins | 2018
Evidence 41 Activity

Activity

40±5% Hemolysis
Toxicity
34 µM
Hemolytic Cytotoxic
40±5% Hemolysis | 34 | µM | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial and Antibiofilm Activities of Helical Antimicrobial Peptide Sequences Incorporating Metal-Binding Motifs. | Biochemistry | 2019
Evidence 42 Activity

Activity

LD50
Toxicity
32 µg/mL
Cytotoxic
LD50 | 32 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 43 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.